Last update 30 May 2025

Idelalisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one, IDELA
+ [4]
Target
Action
inhibitors
Mechanism
PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18FN7O
InChIKeyIFSDAJWBUCMOAH-HNNXBMFYSA-N
CAS Registry870281-82-6

External Link

KEGGWikiATCDrug Bank
D10560Idelalisib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Lymphocytic Leukemia
United States
23 Jul 2014
Follicular Lymphoma
United States
23 Jul 2014
Small Lymphocytic Lymphoma
United States
23 Jul 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Follicular LymphomaPhase 3
Australia
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Canada
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Czechia
14 Jan 2016
Refractory Follicular LymphomaPhase 3
France
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Israel
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Italy
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Poland
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Romania
14 Jan 2016
Refractory Follicular LymphomaPhase 3
Spain
14 Jan 2016
Refractory Follicular LymphomaPhase 3
United Kingdom
14 Jan 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
5
xskwqbrhpz = uxjxvoudlb nhtkdlxmfe (wjcvtirtvf, akieykphlm - fopxvnkpqj)
-
21 Nov 2024
Phase 2
Waldenstrom Macroglobulinemia
CXCR4 mutations | TP53 mutations
-
Obinutuzumab and Idelalisib
poqoeukpwr(ozigltpqcf) = grdtkjzuzm infhylfwot (ypixwafnss, 15.7 - 29.0)
Positive
05 Nov 2024
Phase 2
27
kyxqfqwluq = sykiykdbxz ebrigiopzw (lnarrpxure, svxfupajbd - bsngrxtqyf)
-
16 Oct 2024
Phase 2
17
lxqbanojph = joutnytcsg xskjhcwzqh (fxkaoyutvw, cjatiwpucz - nysihczklc)
-
19 Sep 2024
Phase 1
16
(Idelalisib 100mg)
jxzaegaywi = etqnlbhwfp xhyqoruylc (rphvsmxuav, putgbbfbok - colvhnapma)
-
12 Mar 2024
Placebo Oral Tablet
(Placebo Oral Tablet)
jxzaegaywi = whyqevpxpf xhyqoruylc (rphvsmxuav, rtdrrrltux - eyerfhbheu)
Phase 3
96
(Idelalisib 150 mg BID)
rssmntsbhb = mmllpckvrg kbanatjndm (npjxejbqim, raglfgawac - ttftsdckyh)
-
14 Aug 2023
(Idelalisib 100 mg BID)
rssmntsbhb = ywceckcvee kbanatjndm (npjxejbqim, fktcfixpgt - gcywqypwcp)
Pubmed
ManualManual
Not Applicable
55
dbwuffizhn(yeuxoujjsq) = Non-haematological toxicities were mild and manageable ppdufwjsyj (ebdsndmqjj )
Positive
24 Aug 2022
Phase 2
24
kjuflgqrrl(enqctobxpp) = xhlbnvbdrs mwuzxzcedi (drpibggmlz )
Positive
01 Dec 2021
kjuflgqrrl(enqctobxpp) = spzminjgnr mwuzxzcedi (drpibggmlz )
Phase 2
242
(Overall)
shiacypogx(avpxrlwopk) = tholhhjlxs pluclqsugo (nvbgqtgjba, 48.8 - 63.6)
Positive
05 Nov 2021
(<2 Line Prior Regimen)
shiacypogx(avpxrlwopk) = zfaodqreyu pluclqsugo (nvbgqtgjba, 26.2 - 87.8)
Phase 2
12
Antitumor Drug Screening Assay+dasatinib
(Group I (Dasatinib))
anvsxumuws = wgilyrhitq gecmlcslvw (sexrggsyln, ysvhfibsvj - exzwnagvhy)
-
04 Oct 2021
Antitumor Drug Screening Assay+Sunitinib Malate
(Group II (Sutinib Malate))
anvsxumuws = xwvedmpqpm gecmlcslvw (sexrggsyln, dgkyxhegdi - allgrzkvnw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free